Core Viewpoint - Federal Pharmaceutical (03933) shares increased by nearly 3%, currently trading at HKD 12.17 with a transaction volume of HKD 54.12 million, following the announcement of a significant regulatory milestone for its innovative drug UBT251 [1] Group 1: Company Developments - Federal Pharmaceutical announced that its wholly-owned subsidiary, Federal Biotech (Zhuhai Hengqin) Co., Ltd., received implied clinical trial approval from the National Medical Products Administration of China for UBT251 injection, targeting moderate to severe obstructive sleep apnea (OSA) associated with obesity, effective February 2, 2026 [1] - UBT251 is recognized as China's first chemically synthesized GLP-1/GIP/GCG tri-target receptor agonist new drug, positioning the company prominently in the research field of this category of drugs [1] - The company aims to continue its focus on new product development, enhancing its competitiveness and creativity in the biopharmaceutical industry, which is expected to generate greater returns for the company and its shareholders [1]
港股异动 | 联邦制药(03933)涨近3% 自研1类创新药UBT251注射液OSA适应症获临床试验默示许可